热门资讯> 正文

辉瑞和阿维纳斯的乳腺癌治疗方法将接受FDA审查

2025-08-09 04:29

Arvinas (NASDAQ:ARVN), with its partner Pfizer (PFE), said that the U.S. FDA will review the marketing application for vepdegestrant, to treat patients with advanced or metastatic breast cancer who have previously received endocrine-based therapy.
The FDA has assigned a target action date of June 5, 2026.
Vepdegestrant is being jointly developed by Arvinas and Pfizer.

More on Arvinas

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
Arvinas: A Potential 'Sum Of The Parts' Story
Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes
Arvinas CEO John Houston to retire
Seeking Alpha’s Quant Rating on Arvinas

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。